ADIM
NBIX icon

Alpha DNA Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Alpha DNA Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,732
Closed -$430K – 237
2024
Q3 		$430K Buy
+3,732
New +$512K 0.16% 160
2023
Q4 		– Sell
-4,993
Closed -$562K – 217
2023
Q3 		$562K Buy
+4,993
New +$526K 0.23% 107
2023
Q1 		– Sell
-9,623
Closed -$1.15M – 184
2022
Q4 		$1.15M Buy
9,623
+4,195
+77% +$491K 0.41% 63
2022
Q3 		$576K Buy
+5,428
New +$551K 0.48% 88

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpha DNA Investment Management's NBIX Position: Q4 2024 in Review

Alpha DNA Investment Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 3,732 shares — an estimated $430K sold.

Alpha DNA Investment Management first reported a position in NBIX in Q3 2022 and held it in 4 quarters. The position peaked at $1.15M in Q4 2022. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Alpha DNA Investment Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 3,732 Neurocrine Biosciences shares in Q4 2024, an estimated $430K.
  • Alpha DNA Investment Management first reported a position in Neurocrine Biosciences in Q3 2022 and held it in 4 quarters.
  • Alpha DNA Investment Management's Neurocrine Biosciences position peaked at $1.15M in Q4 2022.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Alpha DNA Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.